WEBVTT 00:00:00.000 --> 00:00:03.140 OK, let's unpack this. We are diving deep today 00:00:03.140 --> 00:00:07.700 into a story of corporate self -destruction. 00:00:07.960 --> 00:00:10.640 But, you know, in the best possible sense. Right. 00:00:10.759 --> 00:00:13.699 We're analyzing a company whose entire history, 00:00:13.800 --> 00:00:17.739 really since 1999, is a masterclass in aggressive, 00:00:17.980 --> 00:00:20.839 focused reinvention. This company systematically 00:00:20.839 --> 00:00:24.629 shed assets. Worth billions. I mean, they essentially 00:00:24.629 --> 00:00:26.989 tore down their foundational identity. Just ripped 00:00:26.989 --> 00:00:29.609 it out. Completely. Only to rebuild itself into 00:00:29.609 --> 00:00:32.210 this highly specialized titan. Yeah. We're talking, 00:00:32.270 --> 00:00:34.070 of course, about Agilent Technologies. And when 00:00:34.070 --> 00:00:36.450 you look at Agilent today, they are. They're 00:00:36.450 --> 00:00:39.030 the indispensable nameplate in any high -end 00:00:39.030 --> 00:00:41.270 laboratory. They provide the sophisticated instruments, 00:00:41.490 --> 00:00:43.710 the diagnostics, the stuff that underpins life 00:00:43.710 --> 00:00:46.049 sciences, advanced clinical research and chemical 00:00:46.049 --> 00:00:48.649 analysis, you know, globally. But the fact that 00:00:48.649 --> 00:00:50.329 they're here, that they're dominating this niche 00:00:50.329 --> 00:00:52.890 is borderline miraculous given where they started. 00:00:53.009 --> 00:00:56.149 They began as this sprawling conglomerate, the 00:00:56.149 --> 00:00:58.630 non -computing half of a true Silicon Valley 00:00:58.630 --> 00:01:02.210 legend. That transformation is. It's just so 00:01:02.210 --> 00:01:04.810 radical. And it wasn't a smooth transition, not 00:01:04.810 --> 00:01:07.430 by a long shot. It was a decades -long strategic 00:01:07.430 --> 00:01:11.719 gamble. punctuated by economic downturns and 00:01:11.719 --> 00:01:15.040 some really ruthless prioritization. So that's 00:01:15.040 --> 00:01:16.680 our mission for you today. We want to understand 00:01:16.680 --> 00:01:19.879 the precise strategic how and why behind this 00:01:19.879 --> 00:01:22.159 evolution. We're using a really comprehensive 00:01:22.159 --> 00:01:24.900 source stack covering Agilent's history, their 00:01:24.900 --> 00:01:27.060 financials, all the big strategic moves. And 00:01:27.060 --> 00:01:29.060 we're really zeroing in on those crucial two 00:01:29.060 --> 00:01:32.799 decades between the dot -com era and today. Yeah. 00:01:32.879 --> 00:01:35.180 And what we're really trying to uncover is the 00:01:35.180 --> 00:01:37.340 core insight of this entire journey. It's the 00:01:37.340 --> 00:01:39.980 aha moment. Right. Exactly. How did a company 00:01:39.980 --> 00:01:42.680 that was dealing primarily in, you know, electronic 00:01:42.680 --> 00:01:44.799 components, communications, testing equipment 00:01:44.799 --> 00:01:48.459 and very traditional medical devices, how did 00:01:48.459 --> 00:01:50.840 they end up pioneering target enrichment for 00:01:50.840 --> 00:01:53.400 next generation sequencing? Or advanced cancer 00:01:53.400 --> 00:01:56.319 diagnostics or even manufacturing nucleic acid 00:01:56.319 --> 00:01:58.579 based therapeutics? It's not just a pivot. That 00:01:58.579 --> 00:02:01.019 word is too small. It's a total corporate metamorphosis. 00:02:01.079 --> 00:02:03.359 And we are going to trace every single step that 00:02:03.359 --> 00:02:05.480 made it successful. To really appreciate the 00:02:05.480 --> 00:02:08.990 scale of Agilent's later... strategic cuts, you 00:02:08.990 --> 00:02:12.129 first have to understand the deep, longstanding 00:02:12.129 --> 00:02:14.669 roots of the businesses they were born from, 00:02:14.789 --> 00:02:17.990 the businesses inside Hewlett Packard, this scientific 00:02:17.990 --> 00:02:21.099 and analytical focus. It wasn't an afterthought. 00:02:21.139 --> 00:02:23.259 It wasn't something they just tacked on. It was 00:02:23.259 --> 00:02:26.560 a deeply ingrained part of the original HP DNA. 00:02:26.879 --> 00:02:29.620 It's truly remarkable how far back this foundation 00:02:29.620 --> 00:02:32.060 goes. You have to rewind all the way to 1965. 00:02:32.759 --> 00:02:35.879 HP, already a computing powerhouse, makes this 00:02:35.879 --> 00:02:38.719 strategic move into scientific equipment. They 00:02:38.719 --> 00:02:41.419 acquire a company called F &M Scientific. And 00:02:41.419 --> 00:02:44.000 F &M, you know, they weren't a household name, 00:02:44.099 --> 00:02:46.699 but they were a small but crucial player. Specifically, 00:02:46.780 --> 00:02:49.349 they were a maker of gas chromatographs. And 00:02:49.349 --> 00:02:51.030 for anyone who's not a chemist, what exactly 00:02:51.030 --> 00:02:53.370 is that? Think of it as a super -powered nose. 00:02:53.750 --> 00:02:56.129 It's a core analytical tool used for separating 00:02:56.129 --> 00:02:58.490 and analyzing compounds in a sample. You inject 00:02:58.490 --> 00:03:00.689 a liquid or gas, it tells you exactly what's 00:03:00.689 --> 00:03:03.669 inside and how much. It's fundamental to everything 00:03:03.669 --> 00:03:05.949 from environmental testing to food safety. So 00:03:05.949 --> 00:03:09.289 that 1965 acquisition, that's the quiet moment 00:03:09.289 --> 00:03:12.360 that seeds the entire future. That's it. That 00:03:12.360 --> 00:03:15.479 single move laid the foundational groundwork 00:03:15.479 --> 00:03:19.080 for Agilent's eventual hyper -focused identity 00:03:19.080 --> 00:03:22.900 in chemical analysis decades later. It was a 00:03:22.900 --> 00:03:26.259 strategic asset, but one that was often overshadowed 00:03:26.259 --> 00:03:29.039 by HP's massive computing and printing divisions. 00:03:29.360 --> 00:03:31.199 Right, because that's what everyone knew HP for, 00:03:31.379 --> 00:03:34.050 printers and calculators. Exactly. And the non 00:03:34.050 --> 00:03:35.729 -computing businesses they inherited weren't 00:03:35.729 --> 00:03:38.069 just add -ons. They were the original sinews 00:03:38.069 --> 00:03:40.750 of the company. You have to consider the HP Medical 00:03:40.750 --> 00:03:43.550 Products division. That had been acquired way 00:03:43.550 --> 00:03:46.430 back in the 1950s. That made it the second oldest 00:03:46.430 --> 00:03:48.569 operating part of the entire Hewlett -Packard 00:03:48.569 --> 00:03:50.900 company. These were not peripheral businesses. 00:03:51.240 --> 00:03:54.439 They were integral, decades -old groups that 00:03:54.439 --> 00:03:56.599 really defined the breadth of the original HP 00:03:56.599 --> 00:03:59.219 mission. So this history is key then. It highlights 00:03:59.219 --> 00:04:01.400 the cultural conflict that was brewing and eventually 00:04:01.400 --> 00:04:05.259 led to the split. 100%. By the late 1990s, HP 00:04:05.259 --> 00:04:07.659 was massive, just enormous. It was a printer 00:04:07.659 --> 00:04:10.599 company, a server company, a medical device company, 00:04:10.740 --> 00:04:12.939 and a lab equipment company all under one roof. 00:04:13.080 --> 00:04:14.840 And you can't manage those the same way, can 00:04:14.840 --> 00:04:18.540 you? You can't. trying to manage the high -volume, 00:04:18.540 --> 00:04:21.819 quick -turnaround PC market alongside the long 00:04:21.819 --> 00:04:25.379 -cycle, high -precision, PhD -driven scientific 00:04:25.379 --> 00:04:28.980 instrument market. It created this untenable 00:04:28.980 --> 00:04:31.269 friction. The cultures were just too different. 00:04:31.410 --> 00:04:33.449 And that friction brings us directly to 1999 00:04:33.449 --> 00:04:36.990 and the necessity of the spinoff. It wasn't really 00:04:36.990 --> 00:04:39.730 a philosophical choice to streamline, was it? 00:04:39.730 --> 00:04:42.449 The market was basically demanding it. Absolutely. 00:04:42.569 --> 00:04:44.649 The source material is quite explicit about this. 00:04:44.949 --> 00:04:47.490 The split was driven by competitive pressure. 00:04:47.629 --> 00:04:50.110 The sheer size, the bureaucracy, the diversity 00:04:50.110 --> 00:04:52.930 of HP, it had become a drag on innovation and 00:04:52.930 --> 00:04:55.129 speed. And they were getting flanked by smaller 00:04:55.129 --> 00:04:57.410 players. Exactly. They needed to compete with 00:04:57.410 --> 00:04:59.829 these smaller, more agile competitors. who were 00:04:59.829 --> 00:05:01.949 focused on single markets and could move much, 00:05:01.949 --> 00:05:04.589 much faster. The decision was born from the difficulty 00:05:04.589 --> 00:05:07.290 HP faced in growing its core revenue while trying 00:05:07.290 --> 00:05:08.689 to stay competitive across so many different 00:05:08.689 --> 00:05:11.149 sectors. The old conglomerate model was failing. 00:05:11.370 --> 00:05:13.470 It was failing in the face of rapid, specialized 00:05:13.470 --> 00:05:15.930 technological change. It just couldn't keep up. 00:05:16.069 --> 00:05:19.490 It's almost poetic that the reason for the spinoff, 00:05:19.490 --> 00:05:22.930 this need for agility, was immediately codified 00:05:22.930 --> 00:05:25.610 into the new company's identity. It really is. 00:05:26.060 --> 00:05:28.480 They were smart about it. They retained the strong 00:05:28.480 --> 00:05:31.019 culture of their parent, the HP way, which was 00:05:31.019 --> 00:05:33.360 all about engineering excellence and integrity. 00:05:33.639 --> 00:05:37.240 And they launched Agilent with that slogan, innovating 00:05:37.240 --> 00:05:39.420 the HP way. Yeah, they were basically saying, 00:05:39.519 --> 00:05:42.000 we'll keep the pedigree, we'll keep the engineering 00:05:42.000 --> 00:05:44.379 chops, but we're going to apply it with speed. 00:05:44.620 --> 00:05:47.160 The branding reinforced this focus, too. The 00:05:47.160 --> 00:05:49.920 name Agilent was explicitly chosen to invoke 00:05:49.920 --> 00:05:52.720 agility. Right, the exact quality they were trying 00:05:52.720 --> 00:05:56.300 to recover. And the famous Starburst logo. That 00:05:56.300 --> 00:05:58.899 was selected to reflect a burst of insight or 00:05:58.899 --> 00:06:01.319 a spark of insight. They weren't just launching 00:06:01.319 --> 00:06:03.000 a new company, they were launching a mindset, 00:06:03.379 --> 00:06:06.079 one that valued speed and specialized engineering 00:06:06.079 --> 00:06:09.199 knowledge over sheer market breadth. So let's 00:06:09.199 --> 00:06:11.279 be really clear about what Agilent was at birth. 00:06:11.420 --> 00:06:13.660 It was not the focused life science company we 00:06:13.660 --> 00:06:15.879 know today. If you were an investor buying into 00:06:15.879 --> 00:06:18.899 that IPO in 1999, what was the actual scope of 00:06:18.899 --> 00:06:20.699 your investment? What were you buying? You were 00:06:20.699 --> 00:06:23.920 still buying a huge company. The original Agilent 00:06:23.920 --> 00:06:26.879 included those scientific instrumentation and 00:06:26.879 --> 00:06:29.910 chemical analysis groups? Yes. But it was still 00:06:29.910 --> 00:06:32.829 deeply, deeply involved in the electronics world. 00:06:33.050 --> 00:06:35.730 Okay, like what? You were buying test and measurement 00:06:35.730 --> 00:06:38.410 equipment for electronics. You were buying optics, 00:06:38.470 --> 00:06:40.790 so LED and laser technology. You were buying 00:06:40.790 --> 00:06:43.889 electronic components. And critically, you were 00:06:43.889 --> 00:06:46.970 buying that vast, revenue -heavy medical equipment 00:06:46.970 --> 00:06:49.730 division that handled things like patient monitoring 00:06:49.730 --> 00:06:52.129 devices in hospitals. So it was really a beast, 00:06:52.389 --> 00:06:55.610 an industrial measurement and analysis conglomerate. 00:06:55.629 --> 00:06:58.959 That's the perfect term for it. still sprawling 00:06:58.959 --> 00:07:01.459 portfolio, the market responded with massive 00:07:01.459 --> 00:07:04.480 confidence. They loved the promise of a leaner, 00:07:04.480 --> 00:07:06.800 more focused future. They did. The initial public 00:07:06.800 --> 00:07:09.899 offering was monumental. It raised $2 .1 billion, 00:07:10.300 --> 00:07:13.540 which set a record for the largest IPO in Silicon 00:07:13.540 --> 00:07:17.040 Valley history at the time. This just underscores 00:07:17.040 --> 00:07:19.860 the initial belief that the HP brand, combined 00:07:19.860 --> 00:07:22.519 with the promise of agility, was enough to command 00:07:22.519 --> 00:07:25.889 a huge premium. The market was essentially giving 00:07:25.889 --> 00:07:27.990 them a vote of confidence to go out and make 00:07:27.990 --> 00:07:30.350 the tough decisions they needed to make. But 00:07:30.350 --> 00:07:32.649 let's pause on that IPO confidence for a second. 00:07:32.730 --> 00:07:35.389 Was that a true vote of confidence in the long 00:07:35.389 --> 00:07:38.389 term strategy of scientific specialization? Or 00:07:38.389 --> 00:07:41.240 was it just... you know, reflecting the massive 00:07:41.240 --> 00:07:44.019 brand recognition and the perceived stability 00:07:44.019 --> 00:07:46.920 of the HP lineage during the tail end of the 00:07:46.920 --> 00:07:48.839 dot com boom. That's a critical distinction. 00:07:49.120 --> 00:07:50.920 And I think you're right. The confidence was 00:07:50.920 --> 00:07:53.439 likely vested in the HP brand and the quality 00:07:53.439 --> 00:07:56.500 of the assets, not necessarily the specific long 00:07:56.500 --> 00:07:58.800 term strategy. Because that strategy hadn't even 00:07:58.800 --> 00:08:00.920 been fully defined yet. Not at all. It was still 00:08:00.920 --> 00:08:03.000 a work in progress. And that confidence, well, 00:08:03.120 --> 00:08:04.800 it would be severely tested almost immediately. 00:08:05.259 --> 00:08:07.319 If you look at the portfolio they took public, 00:08:07.459 --> 00:08:10.180 it was dangerously exposed to the very markets 00:08:10.180 --> 00:08:12.360 that were about to collapse. Semiconductors and 00:08:12.360 --> 00:08:14.540 communications. The heart of the dot -com bubble. 00:08:14.720 --> 00:08:16.920 They were a successful company, but they were 00:08:16.920 --> 00:08:19.319 born into exactly the wrong economic moment. 00:08:19.519 --> 00:08:22.019 So section two is where the high -stakes drama 00:08:22.019 --> 00:08:25.110 really begins. Right after this record -setting 00:08:25.110 --> 00:08:28.050 IPO, the early 2000s economic turbulence hits. 00:08:28.410 --> 00:08:31.389 This period was the crucible that forced Agilent 00:08:31.389 --> 00:08:34.190 to make the brutal strategic cuts they needed 00:08:34.190 --> 00:08:36.970 to survive and ultimately to find their true 00:08:36.970 --> 00:08:40.350 identity. The economic downturn created an instantaneous 00:08:40.350 --> 00:08:44.409 forcing function. It was a trial by fire. Agilent, 00:08:44.490 --> 00:08:46.509 especially through its electronics and communications 00:08:46.509 --> 00:08:49.250 testing divisions, was heavily exposed to the 00:08:49.250 --> 00:08:51.250 collapsing tech markets. Just completely over 00:08:51.250 --> 00:08:53.950 leveraged in that area. Totally. The economic 00:08:53.950 --> 00:08:56.990 uncertainty severely depressed demand, and the 00:08:56.990 --> 00:08:59.309 company was hit with a staggering $500 million 00:08:59.309 --> 00:09:01.950 in canceled orders. Half a billion dollars. Half 00:09:01.950 --> 00:09:03.830 a billion dollars in canceled orders, particularly 00:09:03.830 --> 00:09:05.809 in the communications and semiconductor sectors. 00:09:06.049 --> 00:09:08.590 That's not just a hiccup. It's a near fatal shockwave 00:09:08.590 --> 00:09:11.059 for a nascent public company. And the consequence 00:09:11.059 --> 00:09:14.240 was, well, predictable, but massive in scale. 00:09:14.379 --> 00:09:17.320 A brutal streamlining of operations. Yeah. By 00:09:17.320 --> 00:09:22.019 2003, Agilent had cut 18 ,500 positions. Wow. 00:09:22.360 --> 00:09:24.299 This wasn't trimming the fat for efficiency. 00:09:24.519 --> 00:09:28.320 This was corporate triage. The market was forcing 00:09:28.320 --> 00:09:31.120 Agilent's hand, demanding profitability over 00:09:31.120 --> 00:09:32.820 market breadth. Yeah. And they had to respond. 00:09:33.000 --> 00:09:36.279 And that economic crisis basically dictated their 00:09:36.279 --> 00:09:38.419 first, and you could argue their most, painful 00:09:38.419 --> 00:09:41.350 strategic move. Shedding the legacy health care 00:09:41.350 --> 00:09:44.230 business. This divestiture was the clearest indicator 00:09:44.230 --> 00:09:47.090 that the company was prioritizing strategic focus 00:09:47.090 --> 00:09:50.649 over what looked like short term financial stability. 00:09:50.889 --> 00:09:52.529 Let's talk scale here because I think this is 00:09:52.529 --> 00:09:55.690 often overlooked. In 2001, Agilent sells its 00:09:55.690 --> 00:09:58.009 entire health care and medical products organization 00:09:58.009 --> 00:10:01.350 to Philips Medical Systems. This was not a minor 00:10:01.350 --> 00:10:03.710 adjustment. This was corporate surgery. It really 00:10:03.710 --> 00:10:05.690 was. And remember, this division was the second 00:10:05.690 --> 00:10:08.470 oldest part of the HP empire. It accounted for 00:10:08.470 --> 00:10:11.370 a massive. 60 % of the company's total revenue 00:10:11.370 --> 00:10:13.590 in the year 2000. 60%. Let's just sit with that 00:10:13.590 --> 00:10:16.090 for a moment. Selling a stable, massive 60 % 00:10:16.090 --> 00:10:18.389 revenue stream, a business that was foundational 00:10:18.389 --> 00:10:21.850 to HP to chase a smaller, more specialized niche. 00:10:22.090 --> 00:10:24.909 Isn't that wildly irresponsible in the short 00:10:24.909 --> 00:10:27.409 term? I mean, how did they manage to sell that 00:10:27.409 --> 00:10:30.250 decision to shareholders, especially right after 00:10:30.250 --> 00:10:32.690 a major economic downturn? It was terrifying. 00:10:33.179 --> 00:10:34.899 Financially. There's no other way to put it. 00:10:34.919 --> 00:10:38.200 You are sacrificing immense, stable cash flow. 00:10:38.559 --> 00:10:41.340 But the strategic necessity was just overwhelming. 00:10:41.759 --> 00:10:45.740 Why? What was the fundamental clash? The HP Medical 00:10:45.740 --> 00:10:48.179 Products division operated in a totally different 00:10:48.179 --> 00:10:51.220 sphere. It sold patient -facing monitoring devices, 00:10:51.580 --> 00:10:54.320 defibrillators, hospital equipment. It was a 00:10:54.320 --> 00:10:56.840 high volume, highly regulated market driven by 00:10:56.840 --> 00:10:59.240 relationships with hospital administrators. Okay. 00:10:59.299 --> 00:11:02.360 A B2B sales model, but focused on healthcare 00:11:02.360 --> 00:11:04.679 systems. Right. Meanwhile, the scientific instrument 00:11:04.679 --> 00:11:07.860 business, the gas chromatographs, the mass spectrometers, 00:11:07.960 --> 00:11:10.539 that was a high margin specialized market driven 00:11:10.539 --> 00:11:13.360 by relationships with PhD level researchers and 00:11:13.360 --> 00:11:15.720 lab managers. The sales cycles, the customer 00:11:15.720 --> 00:11:19.289 support, the R &D focus. Everything was different. 00:11:19.429 --> 00:11:21.750 So the culture and the sales cycles clashed fundamentally. 00:11:22.049 --> 00:11:23.990 Precisely. By selling that medical unit, which 00:11:23.990 --> 00:11:26.330 was valued at around $11 billion at the time. 00:11:26.389 --> 00:11:29.850 By selling that, Agilent sent an unmistakable 00:11:29.850 --> 00:11:33.230 signal. They said, we are getting out of commodity 00:11:33.230 --> 00:11:36.370 -driven, high -volume patient care, and we are 00:11:36.370 --> 00:11:39.129 focusing purely on the specialized, high -margin, 00:11:39.129 --> 00:11:41.889 intellectual property -intensive segment of research 00:11:41.889 --> 00:11:44.240 and analytical chemistry. It allowed them to 00:11:44.240 --> 00:11:46.799 concentrate all their engineering and sales resources 00:11:46.799 --> 00:11:49.919 onto a single customer type, the lab scientist. 00:11:50.159 --> 00:11:54.200 This $11 billion exit, though, it was really 00:11:54.200 --> 00:11:56.340 just the dress rehearsal for the ultimate corporate 00:11:56.340 --> 00:11:58.820 simplification, wasn't it? It was. The next step 00:11:58.820 --> 00:12:01.379 was the systematic surgical removal of their 00:12:01.379 --> 00:12:03.960 entire electronics backbone. And that required 00:12:03.960 --> 00:12:05.759 an even greater level of corporate conviction. 00:12:06.159 --> 00:12:08.779 That happened primarily in one massive year. 00:12:09.390 --> 00:12:12.669 2005. 2005 was the year Agilent cemented its 00:12:12.669 --> 00:12:15.250 destiny. They moved decisively away from electronics 00:12:15.250 --> 00:12:17.429 manufacturing. They had proven they could survive 00:12:17.429 --> 00:12:19.830 shrinking the company. And now they applied that 00:12:19.830 --> 00:12:22.169 strategy ruthlessly to the last remaining HP 00:12:22.169 --> 00:12:24.649 legacy businesses. First up was the semiconductor 00:12:24.649 --> 00:12:27.610 IC's business, the actual chip making part of 00:12:27.610 --> 00:12:30.289 the company. Right. That unit was sold to the 00:12:30.289 --> 00:12:32.750 private equity giants. Kohlberg, Kravis Roberts, 00:12:32.970 --> 00:12:36.230 and Silver Lake Partners for $2 .66 billion. 00:12:37.230 --> 00:12:39.610 This single transaction meant the termination 00:12:39.610 --> 00:12:42.210 of 1 ,300 employees and immediately resulted 00:12:42.210 --> 00:12:44.210 in the creation of a new private company. And 00:12:44.210 --> 00:12:46.490 that new company was named Avago Technologies. 00:12:46.809 --> 00:12:49.250 This is essential context because Avago wasn't 00:12:49.250 --> 00:12:51.549 some minor footnote in business history. Not 00:12:51.549 --> 00:12:54.710 at all. Avago later grew, went public, and then 00:12:54.710 --> 00:12:58.169 in a massive deal in 2016, it purchased Broadcom 00:12:58.169 --> 00:13:00.809 Corporation and took on the name Broadcom Limited. 00:13:01.259 --> 00:13:03.820 So just to be clear for everyone listening, Agilent 00:13:03.820 --> 00:13:06.860 is literally the ancestor of one of today's largest, 00:13:06.960 --> 00:13:10.120 most important global semiconductor giants. That's 00:13:10.120 --> 00:13:12.460 right. They consciously chose to discard this 00:13:12.460 --> 00:13:15.299 entire lineage, a multibillion dollar business 00:13:15.299 --> 00:13:17.519 that would become a behemoth all so they could 00:13:17.519 --> 00:13:20.039 focus on selling chromatographs and lab consumables. 00:13:20.600 --> 00:13:23.039 That is the definition of singular focus. It's 00:13:23.039 --> 00:13:25.059 proof that strategic clarity sometimes requires 00:13:25.059 --> 00:13:27.980 you to discard future multi -billion dollar possibilities 00:13:27.980 --> 00:13:30.519 if they dilute your core mission. But they weren't 00:13:30.519 --> 00:13:34.019 even done in 2005. No, not even close. They also 00:13:34.019 --> 00:13:36.840 sold their 47 % stake in the LED manufacturer 00:13:36.840 --> 00:13:40.480 Lumields to Philips for a billion dollars. And 00:13:40.480 --> 00:13:42.740 Lumields, just like the medical products group, 00:13:42.879 --> 00:13:46.000 was an ancient piece of the HP framework. It 00:13:46.000 --> 00:13:48.019 was originally its optoelectronics division. 00:13:48.179 --> 00:13:50.460 Another significant chunk of electronic manufacturing 00:13:50.460 --> 00:13:54.070 gone. And the third major divestiture of 2005 00:13:54.070 --> 00:13:57.370 was the semiconductor test business. So this 00:13:57.370 --> 00:13:59.690 is the equipment used to test chips before they're 00:13:59.690 --> 00:14:02.549 sold, focusing on system -on -chip and memory 00:14:02.549 --> 00:14:05.169 test market areas. Right. And instead of selling 00:14:05.169 --> 00:14:08.529 it outright, Agilent spun this out entirely into 00:14:08.529 --> 00:14:11.529 a new public company called Verigy. Why do that 00:14:11.529 --> 00:14:13.899 instead of just selling it? Well, the strategic 00:14:13.899 --> 00:14:16.259 choice to spin off Verigy as a pure playtest 00:14:16.259 --> 00:14:18.399 company was interesting. It allowed them to maintain 00:14:18.399 --> 00:14:20.259 some market exposure for their shareholders, 00:14:20.519 --> 00:14:22.679 but it removed the management overhead and the 00:14:22.679 --> 00:14:24.919 resource drain from Agilent's core analytical 00:14:24.919 --> 00:14:27.330 instrument strategy. It was a cleaner break. 00:14:27.490 --> 00:14:29.990 So this comprehensive purge, selling the ICs, 00:14:29.990 --> 00:14:32.070 selling the LEDs, spinning off the test equipment, 00:14:32.330 --> 00:14:34.309 it shows a level of corporate simplification 00:14:34.309 --> 00:14:37.110 you rarely see. You really don't. The mission 00:14:37.110 --> 00:14:40.429 of the 2000s was crystal clear. Yeah. Extract 00:14:40.429 --> 00:14:43.129 value from non -core assets and use the resulting 00:14:43.129 --> 00:14:45.590 capital to strengthen the only group left standing, 00:14:45.789 --> 00:14:48.490 analytical measurement. So if we look back at 00:14:48.490 --> 00:14:51.190 that entire decade, what started as a multi -market 00:14:51.190 --> 00:14:54.740 giant. a baby HP really, spread across medical 00:14:54.740 --> 00:14:58.320 components and measurement, had rapidly reorganized. 00:14:58.419 --> 00:15:01.360 It had sold 60 % of its revenue base, divested 00:15:01.360 --> 00:15:04.740 its entire chip making operation, and jettisoned 00:15:04.740 --> 00:15:07.360 its electronic testing unit. They achieved true 00:15:07.360 --> 00:15:10.539 agility, but only by brutally sacrificing billions 00:15:10.539 --> 00:15:13.500 in legacy revenue. The outcome then was a company 00:15:13.500 --> 00:15:16.460 positioned for quality of growth over sheer quantity 00:15:16.460 --> 00:15:18.879 of revenue. Exactly. They made a conscious decision. 00:15:19.080 --> 00:15:22.039 They decided to operate in a high -margin, specialized 00:15:22.039 --> 00:15:25.460 niche, the analytical laboratory, where expertise 00:15:25.460 --> 00:15:28.120 and complex IP create massive barriers to entry. 00:15:28.519 --> 00:15:30.740 They chose that over competing in the cyclical, 00:15:30.799 --> 00:15:32.940 volatile commodity electronics markets where 00:15:32.940 --> 00:15:34.659 they were always fighting giants like Intel or 00:15:34.659 --> 00:15:37.539 Samsung, they had found their beachhead. As we 00:15:37.539 --> 00:15:40.100 transition into the 2010s, the narrative really 00:15:40.100 --> 00:15:41.879 shifts, doesn't it? It goes from cutting and 00:15:41.879 --> 00:15:44.000 survival to targeted build -in and optimization. 00:15:44.519 --> 00:15:46.980 That's a great way to put it. The great divestitures 00:15:46.980 --> 00:15:50.500 are largely concluded and Agilent begins this 00:15:50.500 --> 00:15:53.700 focus phase of acquisitions. They're designed 00:15:53.700 --> 00:15:56.860 to cement life sciences as the core identity 00:15:56.860 --> 00:15:59.580 before the final definitive corporate separation. 00:16:00.080 --> 00:16:02.600 This is the era where they put their money, where 00:16:02.600 --> 00:16:05.220 their strategic focus was. They started targeting 00:16:05.220 --> 00:16:07.980 these specialized technology firms that fit perfectly 00:16:07.980 --> 00:16:10.519 into the burgeoning fields of genomics and clinical 00:16:10.519 --> 00:16:13.360 diagnostics. Right. For instance, in 2011, they 00:16:13.360 --> 00:16:15.559 acquired Halogenomics. It was a Swedish company 00:16:15.559 --> 00:16:18.700 involved in next -generation sequencing technology 00:16:18.700 --> 00:16:20.919 development. And that's a direct signal, right? 00:16:21.019 --> 00:16:23.419 They're looking beyond traditional chemical analysis 00:16:23.419 --> 00:16:26.320 and moving squarely into complex molecular biology. 00:16:26.679 --> 00:16:28.639 It's a huge signal. It shows an understanding 00:16:28.639 --> 00:16:30.759 that the laboratory of the future would be dominated 00:16:30.759 --> 00:16:33.700 by genomics and cell analysis. But the most significant 00:16:33.700 --> 00:16:36.200 move of this period, a financial commitment that 00:16:36.200 --> 00:16:39.379 truly dwarfed the original IPO out, was the agreement 00:16:39.379 --> 00:16:42.759 in May 2012. The DACO acquisition. The agreement 00:16:42.759 --> 00:16:44.940 to buy the Danish cancer diagnostics company 00:16:44.940 --> 00:16:50.000 DACO for $2 .2 billion. $2 .2 billion. That is 00:16:50.000 --> 00:16:52.659 an immense investment. So tell us, why was DACO 00:16:52.659 --> 00:16:54.639 so important to their strategy? What did it give 00:16:54.639 --> 00:16:57.399 them? DACO wasn't just an add -on. It was the 00:16:57.399 --> 00:17:00.799 foundation for their entire diagnostics and genomics 00:17:00.799 --> 00:17:04.059 group. Docco specializes in cancer diagnostics, 00:17:04.059 --> 00:17:06.940 specifically antibodies and reagents used in 00:17:06.940 --> 00:17:09.759 pathology and immunohistochemistry. So analyzing 00:17:09.759 --> 00:17:13.759 tissue samples, biopsies. Exactly. This acquisition 00:17:13.759 --> 00:17:16.539 significantly expanded Agilent's presence deep 00:17:16.539 --> 00:17:19.059 into the high -growth, high -margin clinical 00:17:19.059 --> 00:17:22.289 diagnostics industry. It gave them a direct link 00:17:22.289 --> 00:17:25.329 into patient care through biopsy analysis. It 00:17:25.329 --> 00:17:27.450 provided the necessary scale and credibility 00:17:27.450 --> 00:17:30.029 to be a major player in the clinical world, not 00:17:30.029 --> 00:17:31.569 just the research lab. So they were building 00:17:31.569 --> 00:17:34.390 this new robust core business model, life sciences 00:17:34.390 --> 00:17:36.730 and diagnostics, using the capital they generated 00:17:36.730 --> 00:17:38.650 from selling off all those other pieces. And 00:17:38.650 --> 00:17:40.950 once that new identity was strong enough, they 00:17:40.950 --> 00:17:43.170 were ready for the final act of separation. In 00:17:43.170 --> 00:17:45.130 September 2013, Agilent announced the decision 00:17:45.130 --> 00:17:47.130 to separate into two publicly traded companies. 00:17:47.390 --> 00:17:50.339 This was the last great corporate divorce. They 00:17:50.339 --> 00:17:53.180 needed to shed the final, largest remnant of 00:17:53.180 --> 00:17:56.220 the old HP measurement world to achieve complete 00:17:56.220 --> 00:17:58.960 strategic purity. And that final remnant was 00:17:58.960 --> 00:18:01.640 the electronic measurement business. It was spun 00:18:01.640 --> 00:18:04.180 off into a new entity named Keysight Technologies. 00:18:04.640 --> 00:18:07.400 The formal separation was completed on November 00:18:07.400 --> 00:18:10.799 1st, 2014. And this is so crucial for the listener. 00:18:10.940 --> 00:18:14.420 Keysight is a massive, successful company today. 00:18:14.559 --> 00:18:17.059 It specializes in electronic test equipment, 00:18:17.259 --> 00:18:19.880 the very foundation. of the original Hewlett 00:18:19.880 --> 00:18:22.940 Packard. Agilent gave birth to yet another global 00:18:22.940 --> 00:18:24.839 giant they didn't want to be. It's incredible. 00:18:25.099 --> 00:18:27.519 And this time, Agilent retained the name. The 00:18:27.519 --> 00:18:29.279 company we're discussing today focused entirely 00:18:29.279 --> 00:18:31.680 on the three interconnected areas they had been 00:18:31.680 --> 00:18:33.839 building toward for a decade. Life sciences, 00:18:34.099 --> 00:18:36.539 diagnostics, and applied markets. Their transition 00:18:36.539 --> 00:18:38.970 was finally complete. It wasn't just Keysight 00:18:38.970 --> 00:18:41.009 that was jettisoned in that period, though. We 00:18:41.009 --> 00:18:43.450 also saw some smaller but highly strategic cuts 00:18:43.450 --> 00:18:46.410 as part of this consolidation. In October 2014, 00:18:46.890 --> 00:18:48.569 they announced they were exiting the nuclear 00:18:48.569 --> 00:18:51.730 magnetic resonance business, NMR. That detail 00:18:51.730 --> 00:18:54.710 is so fascinating because on the surface, NMR 00:18:54.710 --> 00:18:57.410 is highly specialized, high -tech analytical 00:18:57.410 --> 00:18:59.450 science, the kind of thing you'd think Agilent 00:18:59.450 --> 00:19:01.750 would keep. Right. It seems to fit. It seems 00:19:01.750 --> 00:19:05.869 to. However, NMR instruments require... Massive 00:19:05.869 --> 00:19:08.670 investment and service infrastructure. They often 00:19:08.670 --> 00:19:11.410 serve a very niche academic market. The strategic 00:19:11.410 --> 00:19:14.509 thinking here was just crystal clear. If a technology, 00:19:14.670 --> 00:19:17.569 even a highly complex one, doesn't cleanly fit 00:19:17.569 --> 00:19:20.089 into the high growth, high margin, increasingly 00:19:20.089 --> 00:19:22.529 clinical life sciences and diagnostic strategy, 00:19:22.789 --> 00:19:24.990 it has to be cut loose. It just proves the rigor 00:19:24.990 --> 00:19:27.690 of their prioritization. No sacred cows. None 00:19:27.690 --> 00:19:30.730 at all. So what does this final split ultimately 00:19:30.730 --> 00:19:33.599 symbolize for their corporate strategy? It means 00:19:33.599 --> 00:19:36.859 they achieved capital focus. That's the key takeaway. 00:19:37.039 --> 00:19:39.500 They could now deploy every single dollar of 00:19:39.500 --> 00:19:42.400 R &D and acquisition capital exclusively into 00:19:42.400 --> 00:19:44.339 the highest growth fields of medical research 00:19:44.339 --> 00:19:47.019 and analytical chemistry. They had moved entirely 00:19:47.019 --> 00:19:49.240 out of the cyclical lower margin electronics 00:19:49.240 --> 00:19:53.279 testing world. It's just. They took the sprawling 00:19:53.279 --> 00:19:55.140 conglomerate, performed a decade of corporate 00:19:55.140 --> 00:19:59.220 surgery, and by 2014, they had a clean. focused 00:19:59.220 --> 00:20:02.059 capital structure ready to go out and dominate 00:20:02.059 --> 00:20:05.380 a specialized high -tech niche. Their ability 00:20:05.380 --> 00:20:08.220 to shrink to grow and to define their boundaries 00:20:08.220 --> 00:20:11.119 so clearly, it makes this a textbook case in 00:20:11.119 --> 00:20:13.619 corporate strategy. The insight here is really 00:20:13.619 --> 00:20:16.299 profound, I think. Agilent didn't just stumble 00:20:16.299 --> 00:20:19.079 into the life sciences boom. They deliberately 00:20:19.079 --> 00:20:21.339 sold off the businesses that were paying the 00:20:21.339 --> 00:20:23.259 bills in the short term, like medical devices, 00:20:23.500 --> 00:20:25.640 and then strategically spun off the businesses 00:20:25.640 --> 00:20:28.440 that provided massive scale electronics, all 00:20:28.440 --> 00:20:30.400 to position themselves perfectly for the molecular 00:20:30.400 --> 00:20:33.000 revolution in biology. Once Agilent achieved 00:20:33.000 --> 00:20:35.299 that clean identity, you know, post -Keysight 00:20:35.299 --> 00:20:37.740 split, they immediately transitioned into what 00:20:37.740 --> 00:20:39.519 we can only describe as an acquisition engine. 00:20:39.680 --> 00:20:43.670 A machine. Truly. they have pursued rapid growth, 00:20:43.789 --> 00:20:46.529 not just through internal R &D, but through systematic 00:20:46.529 --> 00:20:49.470 targeted high value acquisitions. And they were 00:20:49.470 --> 00:20:51.569 designed to build an end -to -end workflow solution 00:20:51.569 --> 00:20:54.009 for the lab scientist. This isn't random buying. 00:20:54.170 --> 00:20:56.549 It's not just growth for growth sick. It's a 00:20:56.549 --> 00:20:59.630 classic ecosystem strategy aimed at filling every 00:20:59.630 --> 00:21:02.910 possible gap in the lab workflow. Exactly. They 00:21:02.910 --> 00:21:05.289 wanted to sell the primary instrument, the specialized 00:21:05.289 --> 00:21:08.630 consumables, the high -tech assays, and the software 00:21:08.630 --> 00:21:11.150 to manage it all. the whole package. So let's 00:21:11.150 --> 00:21:13.150 start with cell analysis technology. This became 00:21:13.150 --> 00:21:16.150 a huge focus area for them. A huge focus. The 00:21:16.150 --> 00:21:18.230 goal here is understanding how living cells function 00:21:18.230 --> 00:21:20.670 and respond to stimuli, which is critical for 00:21:20.670 --> 00:21:23.789 drug discovery. In 2015, they acquired Seahorse 00:21:23.789 --> 00:21:28.160 Bioscience for $235 million. And what did Seahorse 00:21:28.160 --> 00:21:31.099 bring into the portfolio? It brought in crucial 00:21:31.099 --> 00:21:34.220 metabolic cell analysis capabilities. So instead 00:21:34.220 --> 00:21:36.740 of just analyzing chemicals, they could now analyze 00:21:36.740 --> 00:21:39.220 how living cells use energy. It was a major step. 00:21:39.359 --> 00:21:41.599 The Seahorse acquisition was so significant because 00:21:41.599 --> 00:21:44.900 it moved Agilent directly from analyzing, you 00:21:44.900 --> 00:21:47.759 know, dead samples in a vial to analyzing living 00:21:47.759 --> 00:21:50.880 functional systems. And then they doubled down 00:21:50.880 --> 00:21:53.720 on this functional cell analysis focus. In 2018, 00:21:53.880 --> 00:21:56.730 they bought ACAA Biosciences for $250. million 00:21:56.730 --> 00:21:59.210 and Luxell Biosciences in the same year. What 00:21:59.210 --> 00:22:01.349 did those add? They deepened their ability to 00:22:01.349 --> 00:22:04.170 analyze cells in real time, observing processes 00:22:04.170 --> 00:22:07.170 like oxygen consumption and acidification, the 00:22:07.170 --> 00:22:10.180 actual fuel use of a cell. This capability is 00:22:10.180 --> 00:22:12.359 paramount in cancer research and immunology, 00:22:12.460 --> 00:22:14.740 where understanding these metabolic shifts is 00:22:14.740 --> 00:22:17.200 key to developing new therapies. But the capstone 00:22:17.200 --> 00:22:19.859 acquisition in this segment was the massive purchase 00:22:19.859 --> 00:22:23.420 of biotech instruments in 2019 for a staggering 00:22:23.420 --> 00:22:28.839 $1 .165 billion. A huge deal. So biotech is renowned 00:22:28.839 --> 00:22:31.240 for its high -quality life science instrumentation. 00:22:31.279 --> 00:22:33.539 They specialize in automated liquid handling 00:22:33.539 --> 00:22:36.319 and, critically, microplate readers. And the 00:22:36.319 --> 00:22:39.059 biotech deal instantly gave access to a huge 00:22:39.059 --> 00:22:42.160 footprint on the actual lab bench. Microplate 00:22:42.160 --> 00:22:44.819 readers are ubiquitous. They are in every high 00:22:44.819 --> 00:22:47.420 throughput biology lab in the world. This acquisition 00:22:47.420 --> 00:22:49.779 expanded their market share dramatically in core 00:22:49.779 --> 00:22:52.420 life science instrumentation. It moved them beyond 00:22:52.420 --> 00:22:54.880 their traditional strength in expensive analytical 00:22:54.880 --> 00:22:57.059 equipment like mass spectrometers. Right. It 00:22:57.059 --> 00:22:59.039 moved them into dominating the daily routine 00:22:59.039 --> 00:23:01.319 work of the researcher. It was a clear power 00:23:01.319 --> 00:23:03.240 move to create a dominant platform provider. 00:23:03.740 --> 00:23:06.500 Okay, so now let's shift to diagnostics and genomics. 00:23:06.700 --> 00:23:09.380 The clinical side of the business, built on that 00:23:09.380 --> 00:23:12.440 DECO foundation, they continued to invest heavily 00:23:12.440 --> 00:23:15.220 here, recognizing the explosive growth potential 00:23:15.220 --> 00:23:19.019 of genetic information. They did. In 2016, they 00:23:19.019 --> 00:23:22.799 acquired Multiplicom NV. It was a leading European 00:23:22.799 --> 00:23:25.539 diagnosis company specializing in state -of -the 00:23:25.539 --> 00:23:27.880 -art genetic testing technology and products. 00:23:28.079 --> 00:23:30.480 And what was their focus? They were particularly 00:23:30.480 --> 00:23:33.500 focused on congenital disorders and prenatal 00:23:33.500 --> 00:23:36.519 screening. This cemented Agilent's move into 00:23:36.519 --> 00:23:39.460 the clinical application of genomics, complementing 00:23:39.460 --> 00:23:41.220 the research genomics they had started with Halo. 00:23:41.380 --> 00:23:44.339 They also acquired LaserGen Inc. in 2018, which 00:23:44.339 --> 00:23:46.680 reinforced their foundational technology stack 00:23:46.680 --> 00:23:49.339 in the genomics space. They were ensuring they 00:23:49.339 --> 00:23:51.859 had proprietary technology that is indispensable 00:23:51.859 --> 00:23:54.720 to the next generation sequencing workflow. And 00:23:54.720 --> 00:23:56.720 to give the listeners some context here, let's 00:23:56.720 --> 00:23:58.799 talk about why these technologies matter so much. 00:23:58.920 --> 00:24:01.539 The current boom in personalized medicine is 00:24:01.539 --> 00:24:04.200 completely reliant on next gen. Generation Sequencing, 00:24:04.240 --> 00:24:07.579 or NGS. Agilent realized that the challenge wasn't 00:24:07.579 --> 00:24:09.960 just sequencing the entire genome, it was efficiently 00:24:09.960 --> 00:24:13.140 finding the specific, relevant genes within it. 00:24:13.420 --> 00:24:16.460 This is where their role as a pioneer in target 00:24:16.460 --> 00:24:19.059 enrichment comes in. Target enrichment is essentially 00:24:19.059 --> 00:24:22.140 finding the needle in the genomic haystack. When 00:24:22.140 --> 00:24:23.920 you're looking for specific cancer mutations, 00:24:24.140 --> 00:24:26.880 you don't need to sequence all three billion 00:24:26.880 --> 00:24:29.519 base pairs of the human genome. It's just too 00:24:29.519 --> 00:24:32.200 expensive and time -consuming. Right. And target 00:24:32.200 --> 00:24:34.539 enrichment technology, which Agilent specializes 00:24:34.539 --> 00:24:37.380 in, allows researchers to selectively capture 00:24:37.380 --> 00:24:40.380 only the regions of interest. It drastically 00:24:40.380 --> 00:24:43.490 speeds up the process and lowers the cost. This 00:24:43.490 --> 00:24:45.509 makes them a critical partner in the boom of 00:24:45.509 --> 00:24:47.549 modern genomic research. Okay, so let's move 00:24:47.549 --> 00:24:49.509 to the chemical and analytical tools category, 00:24:49.750 --> 00:24:51.750 their core strength inherited all the way from 00:24:51.750 --> 00:24:55.490 1965. They focused acquisitions here on optimizing 00:24:55.490 --> 00:24:58.069 and diversifying this segment. Yeah, in 2016, 00:24:58.210 --> 00:25:00.769 they bought cobalt light systems for about 40 00:25:00.769 --> 00:25:03.710 million pounds. This brought in advanced Raman 00:25:03.710 --> 00:25:05.849 spectroscopy instruments. And what's that used 00:25:05.849 --> 00:25:09.190 for? Raman spectroscopy is used for rapid, non 00:25:09.190 --> 00:25:12.339 -destructive chemical identification. It's highly 00:25:12.339 --> 00:25:15.180 relevant for quality control, like in pharmaceuticals, 00:25:15.180 --> 00:25:17.240 and for security screening, like at airports. 00:25:17.539 --> 00:25:20.779 And in 2018, we saw a flurry of activity aimed 00:25:20.779 --> 00:25:23.980 at both instruments and the high -margin consumables 00:25:23.980 --> 00:25:27.099 needed to run them. They acquired Ultrascientific, 00:25:27.259 --> 00:25:30.019 which provides crucial chemical standards and 00:25:30.019 --> 00:25:33.019 reference materials. The acquisition of Ultrascientific 00:25:33.019 --> 00:25:35.619 shows that holistic strategy at work. It's a 00:25:35.619 --> 00:25:38.220 classic razor and blade business model. You sell 00:25:38.220 --> 00:25:40.779 the expensive machine, the razor, but you ensure 00:25:40.779 --> 00:25:43.319 recurring high -margin revenue by selling the 00:25:43.319 --> 00:25:45.920 specialized, high -quality standards and consumables, 00:25:46.079 --> 00:25:48.240 the blades that are needed to make the machine 00:25:48.240 --> 00:25:50.279 work accurately. It stabilizes their revenue 00:25:50.279 --> 00:25:52.880 streams. Massively. They also acquired Advanced 00:25:52.880 --> 00:25:56.400 Analytical Technologies, or AATI, for $250 million. 00:25:56.720 --> 00:25:59.019 This strengthened their expertise in capillary 00:25:59.019 --> 00:26:01.640 electrophoresis -based molecules. And for anyone 00:26:01.640 --> 00:26:05.119 curious, capillary electrophoresis is a high 00:26:05.119 --> 00:26:08.180 -resolution separation technique. It's vital 00:26:08.180 --> 00:26:11.599 for analyzing complex biomolecules like DNA fragments 00:26:11.599 --> 00:26:14.700 and proteins with incredible precision. So it's 00:26:14.700 --> 00:26:16.720 another key tool for genomics and proteomics. 00:26:17.000 --> 00:26:19.819 And finally, they recognize that a modern, efficient 00:26:19.819 --> 00:26:23.339 lab is fundamentally a digital entity. You can't 00:26:23.339 --> 00:26:26.019 ignore the software. In 2018, they bought Genome 00:26:26.019 --> 00:26:28.660 for digital laboratory management. This acquisition 00:26:28.660 --> 00:26:31.500 was a huge step into the software side of efficiency, 00:26:31.779 --> 00:26:34.119 offering platforms that streamline data handling, 00:26:34.319 --> 00:26:36.700 instrument scheduling, and resource allocation. 00:26:37.180 --> 00:26:39.880 They also acquired Prozyme, Inc., a key producer 00:26:39.880 --> 00:26:42.819 of glycan reagents, another specialized consumable. 00:26:42.920 --> 00:26:45.259 This just shows the ruthless completeness of 00:26:45.259 --> 00:26:47.480 their strategy. They started with the core analytical 00:26:47.480 --> 00:26:50.160 instruments, the GCMS. They added specialized 00:26:50.160 --> 00:26:52.980 cell analysis with Biotech and Seahorse. They 00:26:52.980 --> 00:26:54.859 built a clinical diagnostics unit with Daco. 00:26:55.059 --> 00:26:57.259 And then they filled all the gaps with consumables, 00:26:57.359 --> 00:26:59.640 high -resolution separation tools, and the digital 00:26:59.640 --> 00:27:02.339 platform to manage it all. This systematic approach 00:27:02.339 --> 00:27:05.400 has resulted in a really comprehensive current 00:27:05.400 --> 00:27:08.559 core product portfolio. Agile now serves the 00:27:08.559 --> 00:27:11.819 entire spectrum. Analytical laboratories, clinical 00:27:11.819 --> 00:27:14.339 markets, and routine diagnostics. Let's just 00:27:14.339 --> 00:27:16.519 ground this by listing some of their key platforms 00:27:16.519 --> 00:27:19.660 today. They dominate in gas and liquid chromatography. 00:27:19.759 --> 00:27:21.599 Those are the foundational tools used globally 00:27:21.599 --> 00:27:23.920 in environmental testing, quality control, food 00:27:23.920 --> 00:27:26.759 safety, toxicology. Everywhere. They're immense 00:27:26.759 --> 00:27:29.160 in mass spectrometry and spectroscopy. And on 00:27:29.160 --> 00:27:31.380 the biological side, they offer microarrays. 00:27:32.040 --> 00:27:34.819 Ophiaceae probes, which are DNA probes used to 00:27:34.819 --> 00:27:37.680 literally tag and visualize specific genetic 00:27:37.680 --> 00:27:39.960 material under a microscope. And the essential 00:27:39.960 --> 00:27:41.759 target enrichment technology we just talked about. 00:27:41.900 --> 00:27:43.960 They even sell vacuum technologies, which just 00:27:43.960 --> 00:27:46.259 demonstrates that they provide the entire technical 00:27:46.259 --> 00:27:48.900 infrastructure necessary for a modern lab environment, 00:27:49.099 --> 00:27:51.579 from the big machine to the smallest pump. It's 00:27:51.579 --> 00:27:54.460 not just a vendor relationship anymore. They 00:27:54.460 --> 00:27:57.900 invest heavily in R &D. both internally and through 00:27:57.900 --> 00:28:00.160 strategic collaborations with leading universities. 00:28:00.579 --> 00:28:03.140 They are positioning themselves not just as a 00:28:03.140 --> 00:28:05.660 seller of equipment, but as a technological leader, 00:28:05.859 --> 00:28:08.579 co -developing the next generation of knowledge 00:28:08.579 --> 00:28:12.079 in life sciences and chemical analysis. They 00:28:12.079 --> 00:28:14.200 are driving the research that they will later 00:28:14.200 --> 00:28:17.279 profit from. So stepping back, let's synthesize 00:28:17.279 --> 00:28:19.200 the company's current status and look toward 00:28:19.200 --> 00:28:21.799 the future based on this highly focused entity 00:28:21.799 --> 00:28:25.200 they have become since 2014. The structure they 00:28:25.200 --> 00:28:27.940 settled into is a perfect reflection of their 00:28:27.940 --> 00:28:30.099 strategic focus. Yeah, their current organization 00:28:30.099 --> 00:28:32.680 is built around three key operational pillars. 00:28:33.019 --> 00:28:35.720 The first is the Life Sciences and Applied Markets 00:28:35.720 --> 00:28:39.160 Group, or LSAC. This deals with their core instrumentation. 00:28:39.450 --> 00:28:42.049 the chromatographs, spectrometers, the biotech 00:28:42.049 --> 00:28:43.829 instruments. It's the hardware for research. 00:28:44.029 --> 00:28:46.329 The second is the Diagnostics and Genomics Group, 00:28:46.450 --> 00:28:49.009 DGG, which handles the clinical and genetic testing 00:28:49.009 --> 00:28:51.329 products. This is largely built out through the 00:28:51.329 --> 00:28:53.430 DECO and multiple -cum acquisitions. It's the 00:28:53.430 --> 00:28:55.750 patient -facing side of the business. And the 00:28:55.750 --> 00:29:07.880 third, the Agilent CrossLab Group. So not just 00:29:07.880 --> 00:29:10.200 fixing the machines. No, everything. Enterprise 00:29:10.200 --> 00:29:12.279 asset management, service contracts, software 00:29:12.279 --> 00:29:14.259 maintenance. This is the realization that in 00:29:14.259 --> 00:29:16.660 modern science, the service contract and the 00:29:16.660 --> 00:29:19.319 software are often more stable and more profitable 00:29:19.319 --> 00:29:21.779 than the physical hardware itself. So Agilent 00:29:21.779 --> 00:29:24.359 wants to sell the razor and the blades. And CrossLab 00:29:24.359 --> 00:29:26.720 is that high margin blade division. Precisely. 00:29:26.759 --> 00:29:29.160 And the success of this decades -long streamlining 00:29:29.160 --> 00:29:31.779 process is reflected so clearly in their 2024 00:29:31.779 --> 00:29:35.119 financial snapshot. The aggressive cuts and focused 00:29:35.119 --> 00:29:37.460 acquisitions were highly effective. They reported 00:29:37.460 --> 00:29:40.539 $6 .51 billion. in revenue and a really strong 00:29:40.539 --> 00:29:44.099 operating income of $1 .49 billion. They maintain 00:29:44.099 --> 00:29:47.359 total assets of $11 .8 billion and employ about 00:29:47.359 --> 00:29:50.660 17 ,900 people globally. These are the numbers 00:29:50.660 --> 00:29:53.799 of a highly successful, focused leader dominating 00:29:53.799 --> 00:29:56.180 a niche market. It is the financial proof that 00:29:56.180 --> 00:29:58.779 the strategy worked. By exiting the volatile 00:29:58.779 --> 00:30:01.039 commodity markets of electronics and shedding 00:30:01.039 --> 00:30:03.859 the lower margin legacy medical business, they 00:30:03.859 --> 00:30:06.619 created a high -margin, specialized revenue stream 00:30:06.619 --> 00:30:09.339 that commands strong profits. We should also 00:30:09.339 --> 00:30:11.839 note the recent leadership transition. Padraig 00:30:11.839 --> 00:30:14.799 McDonald succeeded Mike McMullin as CEO on May 00:30:14.799 --> 00:30:18.059 1st, 2024. And that signals a new chapter, one 00:30:18.059 --> 00:30:21.599 focused on digital integration and therapeutic 00:30:21.599 --> 00:30:24.119 expansion. That digital strategy is crucial. 00:30:24.380 --> 00:30:26.900 Lab efficiency is increasingly defined by software 00:30:26.900 --> 00:30:30.079 and connectivity. Agilent is absolutely focused 00:30:30.079 --> 00:30:32.740 on integrating their physical instruments with 00:30:32.740 --> 00:30:35.500 digital tools to improve lab workflow, efficiency, 00:30:35.819 --> 00:30:38.440 and productivity. It's about leveraging the connectivity 00:30:38.440 --> 00:30:40.420 of all their instruments to optimize laboratory 00:30:40.420 --> 00:30:43.200 performance, reduce errors, and minimize downtime. 00:30:43.539 --> 00:30:45.880 A prime example of this commitment came in 2020 00:30:45.880 --> 00:30:48.339 with the introduction of CrossLab Virtual Assist. 00:30:48.579 --> 00:30:50.380 Which is a mobile app. It's a mobile app, yeah, 00:30:50.500 --> 00:30:53.359 but one specifically designed to facilitate high 00:30:53.359 --> 00:30:56.480 -quality remote technical support. And that minimizes 00:30:56.480 --> 00:30:59.059 the agony of waiting for a technician to travel 00:30:59.059 --> 00:31:02.150 to a lab in some remote location, right? For 00:31:02.150 --> 00:31:04.170 a complex, high -stakes research environment, 00:31:04.470 --> 00:31:07.529 that immediate, targeted assistance to complex 00:31:07.529 --> 00:31:10.650 instrument issues delivered digitally is absolutely 00:31:10.650 --> 00:31:12.789 crucial for maintaining the research timeline. 00:31:13.130 --> 00:31:15.250 And tying into modern corporate responsibility, 00:31:15.769 --> 00:31:18.230 their digital advancements also directly impact 00:31:18.230 --> 00:31:20.950 sustainability. CrossLab Connect, for example, 00:31:21.089 --> 00:31:23.809 helps improve lab optimization by enabling more 00:31:23.809 --> 00:31:25.869 efficient utilization of instruments. How so? 00:31:26.150 --> 00:31:28.150 By running them only when necessary at optimal 00:31:28.150 --> 00:31:31.319 loads. This directly lowers energy consumption. 00:31:31.519 --> 00:31:34.259 So it connects their tech strategy directly to 00:31:34.259 --> 00:31:36.299 the green initiatives that are increasingly important 00:31:36.299 --> 00:31:39.019 for major universities and pharmaceutical companies. 00:31:39.240 --> 00:31:41.000 Finally, we have to look at where they are placing 00:31:41.000 --> 00:31:43.160 their biggest, most capital intensive future 00:31:43.160 --> 00:31:45.900 bets. Historically, Agilent has been about analysis 00:31:45.900 --> 00:31:48.700 and diagnostics. Right. But in early 2023, the 00:31:48.700 --> 00:31:52.180 company announced a massive $725 million expansion 00:31:52.180 --> 00:31:55.359 of its nucleic acid based therapeutics manufacturing 00:31:55.359 --> 00:31:58.519 facility in Frederick, Colorado. That is an immense. 00:31:58.670 --> 00:32:01.829 commitment. And it places Agilent squarely into 00:32:01.829 --> 00:32:04.769 the high growth sector of oligonucleotide manufacturing. 00:32:05.210 --> 00:32:07.720 What are those exactly? Oligonucleotides are 00:32:07.720 --> 00:32:09.900 the key building blocks for next generation therapies. 00:32:10.180 --> 00:32:13.099 Things like mRNA vaccines and gene silencing 00:32:13.099 --> 00:32:15.940 drugs. This demonstrates a strategic shift toward 00:32:15.940 --> 00:32:18.299 manufacturing components for the future of medicine. 00:32:18.660 --> 00:32:21.599 They're moving beyond simply analyzing DNA and 00:32:21.599 --> 00:32:24.579 proteins to enabling the actual creation of advanced 00:32:24.579 --> 00:32:27.380 therapies. So this investment signals that Agilent 00:32:27.380 --> 00:32:30.599 is moving up the value chain into biopharma manufacturing 00:32:30.599 --> 00:32:34.640 support, a high stakes, high reward sector. It 00:32:34.640 --> 00:32:36.839 suggests that. The instruments they sell today 00:32:36.839 --> 00:32:39.380 are fueling the research that requires the manufacturing 00:32:39.380 --> 00:32:41.519 capacity they are building tomorrow. They're 00:32:41.519 --> 00:32:43.900 creating a full circle synergy. It's the logical 00:32:43.900 --> 00:32:46.359 ultimate endpoint of the journey, isn't it? It 00:32:46.359 --> 00:32:48.359 really is. They started by analyzing chemicals. 00:32:48.539 --> 00:32:51.759 They evolved to analyzing DNA and cells. Now 00:32:51.759 --> 00:32:54.059 they are enabling the scaled production of the 00:32:54.059 --> 00:32:56.099 therapeutic molecules that are defined by that 00:32:56.099 --> 00:32:58.339 analysis. They are positioning themselves to 00:32:58.339 --> 00:33:00.759 be indispensable not just for discovery, but 00:33:00.759 --> 00:33:03.450 for manufacturing the cure. We've covered a massive 00:33:03.450 --> 00:33:05.670 amount of corporate history today, tracking a 00:33:05.670 --> 00:33:08.190 story of relentless, focused corporate surgery. 00:33:08.450 --> 00:33:11.250 So let's quickly review the core strategic takeaways 00:33:11.250 --> 00:33:14.490 from Agilent's evolution. Well, we tracked Agilent's 00:33:14.490 --> 00:33:16.369 journey from being this collection of diverse, 00:33:16.569 --> 00:33:19.670 non -computing business units inside HP to becoming 00:33:19.670 --> 00:33:22.170 a highly focused high -tech instrument and services 00:33:22.170 --> 00:33:25.250 specialist. Right. The key was a rigorous, nearly 00:33:25.250 --> 00:33:27.730 two -decade process of strategic divestiture. 00:33:28.049 --> 00:33:31.609 It started with that $11 billion medical revenue 00:33:31.609 --> 00:33:34.180 sale. followed by shedding massive electronics 00:33:34.180 --> 00:33:37.259 assets like Avago, which became Broadcom, and 00:33:37.259 --> 00:33:39.819 finally separating Keysight Technologies. And 00:33:39.819 --> 00:33:42.259 that divestiture wasn't a failure. It was a success 00:33:42.259 --> 00:33:45.180 of strategic intent. It was followed by an aggressive, 00:33:45.299 --> 00:33:48.200 targeted acquisition phase, highlighted by those 00:33:48.200 --> 00:33:51.519 huge, defining deals, like the $2 .2 billion 00:33:51.519 --> 00:33:54.539 purchase of DACO for clinical diagnostics. And 00:33:54.539 --> 00:33:57.680 the $1 .165 billion acquisition of Biotech for 00:33:57.680 --> 00:34:00.380 lab instrumentation. These moves allowed them 00:34:00.380 --> 00:34:02.240 to completely dominate the... high margin lab 00:34:02.240 --> 00:34:04.519 technology ecosystem. So if we connect all the 00:34:04.519 --> 00:34:07.180 dots, the company that started with gas chromatographs 00:34:07.180 --> 00:34:10.800 back in 1965, a basic piece of analytical chemistry 00:34:10.800 --> 00:34:13.659 equipment, is now enabling target enrichment 00:34:13.659 --> 00:34:15.840 for next generation sequencing, sophisticated 00:34:15.840 --> 00:34:18.980 cell analysis and manufacturing nucleic acid 00:34:18.980 --> 00:34:21.480 based therapeutics. It's the perfect illustration 00:34:21.480 --> 00:34:24.260 of corporate evolution guided by strategic focus 00:34:24.260 --> 00:34:27.780 and an almost ruthless ability to cut loose any 00:34:27.780 --> 00:34:30.519 business, no matter how profitable, that doesn't 00:34:30.519 --> 00:34:33.130 fit. the singular core vision. So we leave you 00:34:33.130 --> 00:34:35.409 with one final provocative thought to consider, 00:34:35.510 --> 00:34:38.070 circling back to the sheer financial scale of 00:34:38.070 --> 00:34:40.710 their strategic moves. Think about how Agilent's 00:34:40.710 --> 00:34:43.269 biggest external moves transitioned from spinning 00:34:43.269 --> 00:34:46.409 off capital with that record $2 .1 billion IPO 00:34:46.409 --> 00:34:50.250 in 1999 to aggressively spending capital strategically. 00:34:50.730 --> 00:34:53.530 Like the $2 .2 billion on DACO and the $1 .165 00:34:53.530 --> 00:34:56.369 billion on biotech to buy their way into dominance. 00:34:56.670 --> 00:35:00.050 And now they're committing $725 million to nucleic 00:35:00.050 --> 00:35:02.530 acid therapeutics manufacturing. This signals 00:35:02.530 --> 00:35:05.550 a new stage, manufacturing enablement. So the 00:35:05.550 --> 00:35:08.409 question is, what kind of high -value biopharma 00:35:08.409 --> 00:35:10.409 -enabling acquisitions would define their next 00:35:10.409 --> 00:35:13.210 five years? Maybe something in supply chain control 00:35:13.210 --> 00:35:17.269 or specialized purification technologies or even 00:35:17.269 --> 00:35:20.530 advanced robotics for manufacturing. As Agilent 00:35:20.530 --> 00:35:22.590 solidifies its position as an essential partner 00:35:22.590 --> 00:35:25.070 in the therapeutic manufacturing world, what's 00:35:25.070 --> 00:35:27.050 next? That's something to think about until the 00:35:27.050 --> 00:35:27.869 next Deep Dive.